News
-
-
-
-
PRESS RELEASE
Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research initiates coverage on MaaT Pharma SACA with a BUY rating and EUR 17 price target. MaaT Pharma focuses on microbiome-based therapies for oncology, with high clinical impact and late-stage pipeline -
-
-
-
-
-